Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A six-week, randomized, double-blind, multicenter, fixed-flexible dose, placebo-controlled study evaluating the efficacy and safety of oral ziprasidone in outpatients with bipolar I depression

Next Previous
Trial Profile

A six-week, randomized, double-blind, multicenter, fixed-flexible dose, placebo-controlled study evaluating the efficacy and safety of oral ziprasidone in outpatients with bipolar I depression

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Mar 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ziprasidone (Primary)
  • Indications Bipolar I disorders
  • Focus Therapeutic Use
  • Sponsors Pfizer; Viatris Inc

Most Recent Events

  • 01 Apr 2009 Planned number of patients changed from 539 to 536 as reported by ClinicalTrials.gov.
  • 21 Aug 2008 Status changed from recruiting to active, no longer recruiting.
  • 15 Apr 2008 The expected completion date for this trial has changed from 1 Feb 2008 to 1 Jun 2008, according to ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top